Abbott Selects Two Antigen Targets from Celera Genomics for Cancer Therapeutic Development
Celera Genomics announced last week that two of its antigen targets have been selected for further investigation by Abbott Laboratories for cancer therapeutic development.
The targets were developed by Celera Genomics over the last year, since the company signed a collaboration agreement (see PM 7/16/2004) with Abbott to use proteomic technologies to develop cell surface antigens that could serve as cancer therapeutics.
Financial terms for the agreement were not provided.
PerkinElmer, Nonlinear Dynamics to Co-market Proteomics Tools
PerkinElmer will offer its customers Nonlinear Dynamics' complete line of proteomics software as part of an expanded business agreement.
The deal includes NLD's ProMST mass spectrometry bioinformatics package and Progenesis image-analysis software, which PerkinElmer said it hopes will complement its high-content proteomics instrumentation platforms, such as the prOTOF 2000 MALDI-TOF orthogonal mass spectrometer and ProXPRESS imaging platform.
In addition, the two companies will co-develop new proteomics software that will combine NLD's data-analysis expertise with PerkinElmer's imaging, detection, and mass spectrometry instruments.
Agilent and Proteome Systems Pen Mass Spec Software Agreement
Agilent Technologies and Proteome Systems will collaborate on a combined platform for glycoprotein analysis, the companies said this week.
Under the terms of the agreement, Proteome Systems will make its GlycomIQ software compatible with Agilent's XCT, XCT Plus and XCT Ultra ion-trap mass spectrometers, the companies said.
Financial terms of the deal were not disclosed.
The companies said that the combined products are expected to be available this summer. In addition, the companies will jointly develop applications and seminars as part of the marketing agreement.
GlycomIQ comprises kits, consumables, and informatics software for automated analysis of protein glycosylation.
MorphoSys' Antibodies by Design and JPT Peptide Technologies to Co-Market Products and Services
MorphoSys' Antibodies by Design division and JPT Peptide Technologies of Germany will co-market their antibody and peptide products and services, the companies said this week.
Under the agreement, Antibodies by Design, of Martinsried, and JPT, a subsidiary of Berlin-based Jerini, will offer each other's products and services to customers worldwide, except for Japan.
Antibodies by Design develops monoclonal antibodies, while JPT offer complementary peptide-based services and products.
MolPAGE Consortium Aims to Find Biomarkers for Diabetes, Vascular Disease
A European consortium of 18 academic institutions, biotechnology companies, and pharmaceutical firms has been funded by €12 million ($15.5 million) from the European Union to identify biomarkers for diabetes and vascular disease.
The consortium, called the Molecular Phenotyping to Accelerate Genomic Epidemiology Consortium, or MolPAGE, is led by Mark McCarthy and John Bell at Oxford University.
The diabetes research program aims to use genomic, proteomic, and metabonomic technologies to identify biomarkers that are able to highlight individuals likely to suffer from diabetes and vascular disease before they show any of the symptoms, biochemical abnormalities, or other features typically used in the diagnosis of these conditions.
"Whilst the use of well-established parameters like blood glucose, cholesterol, and lipids for the diagnosis of diabetes is extremely valuable, the recent advent of gene-regulating drugs for the treatment of diabetes has highlighted the need for a deeper molecular understanding of its causes," said Bell.
"Using new technologies to study and characterize cohorts of patients offers the potential to identify biomarkers that predict the disease, determine risk, and relate to disease activity as well as response to therapy."
MolPAGE consortium members include: the University of Oxford; Oxford Genetic Technology; Centre National de Genotypage; Epigenomics; Biovision; Novo Nordisk; the Royal Institute of Technology; Affibody; Charles University; the European Bioinformatics Institute; the Institute of Mathematics & Computer Science of the University of Latvia; Imperial College of Science; Technology and Medicine; the University of Pavia; Gyros; Guys and St Thomas Hospital NHS Trust; Uppsala University; and Roche.
Nine Nature Journals Agree to Submit Interaction Data to Blueprint's BIND Prior to Publication
The Blueprint Initiative said this week that it has signed an agreement with Nature Publishing Group to have nine Nature-branded journals submit manuscripts containing biomolecular interaction data to Blueprint's Biomolecular Interaction Network Database in advance of publication.
According to Blueprint, this step will allow BIND to provide identifiers in publications with interaction data in a manner similar to the publication of GenBank identifiers for publications with novel sequences.
"We have been working with Blueprint North America since 2003 to advance emerging interaction data to the scientific community," Timo Hannay, associate director of web publishing at NPG, said in a statement. "We have implemented a process that can confidentially forward them pre-publication manuscripts from Nature-branded titles, enabling the relevant BIND records to be published simultaneously with the papers."
To date, Blueprint said, BIND has provided nearly 150 BIND identifiers for publication in Nature Cell Biology, including 18 in the February 2005 issue.
The nine NPG journals include Cell Death & Differentiation, Molecular Systems Biology, Nature, Nature Biotechnology, Nature Cell Biology, Nature Genetics, Nature Immunology, Nature Medicine, Nature Methods, Nature Neuroscience, Nature Structural & Molecular Biology, Oncogene, and the EMBO Journal.
GE and Lilly Partner on Alzheimer's Diagnostics, Therapeutics
General Electric, through its Global Research and GE Healthcare units, has inked a research collaboration with Eli Lilly for the discovery of diagnostics and therapeutics for Alzheimer's disease, the companies said this week.
According to the companies, the research collaboration will target beta-amyloid protein.
GE Healthcare will have access to Lilly's molecular libraries to search for compounds that might be used in targeted diagnostic imaging agents for Alzheimer's.
Lilly will subsequently have access to any diagnostic agents developed by GE to use in the discovery of Alzheimer's therapeutics, the companies said.
Dharmacon to Supply siRNA Libraries to Cancer Research UK
RNAi reagent provider Dharmacon said this week that it has signed a deal under which it will provide its siRNA libraries to Cancer Research UK for use in drug discovery and development.
According to Dharmacon, the libraries will initially include protein kinase genes and associated pathways. They will be used by Cancer Research UK scientists studying signal transduction, protein phosphorylation, secretory pathways, and biochemical regulatory mechanisms.
If this research is successful, Cancer Research UK intends to use larger siRNA libraries, Julian Downward, principal scientist at the Signal Transduction Laboratory at the research institute, said in a statement.
Specific terms of the arrangement were not disclosed.